Ipsen Doubles Down On FOP With Blueprint Pact
Deal could be worth up to $535m
With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.
You may also be interested in...
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
Ipsen’s chief business officer tells Scrip that buying Canada’s Clementia Pharmaceuticals this year gave the French group’s rare disease operations an “anchor asset” to build on.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.